DrugBiological
Cabiralizumab clinical trials
Also written FPA008 and BMS-986227.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 4
Bristol-Myers Squibb (2) · Five Prime Therapeutics, Inc. (2) · University of Michigan Rogel Cancer Center (1) · Hitendra Patel (1) · University of Chicago (1) · NYU Langone Health (1)
Often tested with
Tested in the same studies.
Nivolumab (4) · Gemcitabine (2) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Fluorouracil (1) · Leucovorin (1) · Urelumab (1) · Relatlimab (1)
Studies
Open first, then newest update. How each study uses cabiralizumab is read from its arms, and is right about nine times in ten.
Testing it · 8
- Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell LymphomaCompletedPhase 2University of Michigan Rogel Cancer CenterNCT03927105Written as cabiralizumab
- Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic CancerCompletedPhase 2Hitendra PatelNCT03697564Written as Cabiralizumab
- A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic CancerCompletedPhase 2Bristol-Myers SquibbNCT03336216Written as Cabiralizumab
- Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for CancerCompletedPhase 1University of ChicagoNCT03431948Written as Cabiralizumab
- An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker AssessmentCompletedPhase 1Bristol-Myers SquibbNCT03335540Written as Cabiralizumab
- Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis SubjectsTerminatedPhase 1Five Prime Therapeutics, Inc.NCT01962337Written as FPA008
- Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic CancerTerminatedPhase 2NYU Langone HealthNCT03599362Written as Nivolumab + Cabiralizumab
- Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell TumorCompletedPhase 1/2Five Prime Therapeutics, Inc.NCT02471716Written as FPA008
Given in every arm · 4 — cabiralizumab is usual care beside what is tested
- Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast CancerTerminatedPhase 1/2Washington University School of MedicineNCT04331067Written as Cabiralizumab
- APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaCompletedPhase 1Yale UniversityNCT03502330Written as Cabiralizumab
- Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced CancersCompletedPhase 1Five Prime Therapeutics, Inc.NCT02526017Written as Cabiralizumab
- A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has SpreadCompletedPhase 1Bristol-Myers SquibbNCT03158272Written as Cabiralizumab
Codes
What other systems call cabiralizumab · ClinicalTrials.gg INT001850
- UNII (FDA) 5FJL6W0640CABIRALIZUMABConfirmed FDA, Wikidata
- Wikidata Q29345603CabiralizumabConfirmed FDA, Wikidata
- NCI Thesaurus C123831CabiralizumabOne source FDA
- DrugBank DB15082One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5FJL6W0640 | CABIRALIZUMAB | Confirmed FDA, Wikidata |
| Wikidata | Q29345603 | Cabiralizumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C123831 | Cabiralizumab | One source FDA |
| DrugBank | DB15082 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.